Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Angler101on Jul 30, 2023 3:51pm
144 Views
Post# 35563892

RE:Roche anti-TIGIT hope turns to Tecentriq

RE:Roche anti-TIGIT hope turns to TecentriqNotable...Thank you once again for your (and other’s) constant barrage of much appreciated incredibly pertinent information supporting the argument for our little virus finally getting bought out and eventually approved for helping out many thousands and perhaps many millions of cancer victims in what seemingly could be scores of indications. You and other posters here are obviously very intellectual and well-read on anything biotech. Judging buy all the info you all have laid out, I, as a layman, am very optimistic that we will indeed see a buyout deal itntdf....Lol...In fact, I can’t see how it could not happen at this point.......A question I’ve wanted to ask, for some time now, if someone wouldn’t mind responding to is, “What biotech do any of you see as being the next big buyout candidate, other than ONCY?
<< Previous
Bullboard Posts
Next >>